Journal: AAPS PharmSciTech

Article Title: AddaVax Formulated with PolyI:C as a Potential Adjuvant of MDCK-based Influenza Vaccine Enhances Local, Cellular, and Antibody Protective Immune Response in Mice

doi: 10.1208/s12249-021-02145-0

Figure Lengend Snippet: Fluorescence imaging after administration of H3 combined with adjuvant in mice. Cy5.5-H3 alone or with AP, PolyI:C, and AddaVax were injected into BALB/c mice (100 µL/mouse), and fluorescence images were acquired using PE IVIS Lumina XRMS. Real-time monitoring of H3 antigen persistence at the injection sites or migration by in vivo fluorescence imaging

Article Snippet: The mice were anesthetized with 4% isoflurane exposure; then, 670 nm irradiation was implemented to the whole mouse for fluorescence images using PE IVIS Lumina XRMS (PerkinElmer, USA).

Techniques: Fluorescence, Imaging, Adjuvant, Injection, Migration, In Vivo

Journal: Nano Convergence

Article Title: Tumor-specific biochemical nanoconversion of self-assembled peptide-conjugated paclitaxel-docetaxel-based nanoparticles

doi: 10.1186/s40580-025-00487-0

Figure Lengend Snippet: In vitro, cathepsin B cleavage, cellular toxicity and fluorescence imaging of (Ac)FRRF-DTX NPs. HPLC analysis of (Ac)FRRF-DTX NPs incubated without ( a ) or with ( b ) enzyme reaction buffer containing cathepsin B for different time points (0–72 h). ( c ) LC-MS analysis of PTXm during the cathepsin B cleavage experiment. ( d ) The assessment of cathepsin B activity levels in HDFa, Hep G2, CT26.wt, and A549 cell lines ( n = 3). ( e ) Evaluation of anticancer efficacy on Hep G2 cells treated with DTX, PTX, PTXm, (Ac)FRRF, (Ac)FRRF-DTX NPs and de-Boc-DTX ( n = 5 − 6). ( f ) Cellular uptake of RITC-PTX and RITC-(Ac)FRRF-DTX NPs in Hep G2 cells (Scale bar = 50 μm). ( g ) Data quantifying the fluorescence intensity over time of (Ac)FRRF-DTX NPs and PTX ( n = 3). ( h ) Fluorescent microscopy imaging observing cell death in Hep G2 cells treated with PTX, PTXm and (Ac)FRRF-DTX NPs (Scale bar = 50 μm). ( i ) Quantification of fluorescence intensity from nucleic acid staining using ImageJ software ( n = 5). ( j ) microtubule binding of PTX, PTXm and (Ac)FRRF-DTX NPs (Scale bar = 50 μm). ( k ) Quantification of fluorescence intensity from Microtubule Cytoskeleton Dye using ImageJ software ( n = 5). ( l ) Confocal images of (Ac)FRRF-DTX NPs (Scale bar = 10 μm). *p < 0.05, **p < 0.01 and ***p < 0.001

Article Snippet: Also, the fluorescence intensity in nude mice was captured using a precision fluorescence analyzer (FOBI, CELLGENTEK, Republic of Korea).

Techniques: In Vitro, Fluorescence, Imaging, Incubation, Liquid Chromatography with Mass Spectroscopy, Activity Assay, Microscopy, Staining, Software, Binding Assay

Journal: Nano Convergence

Article Title: Tumor-specific biochemical nanoconversion of self-assembled peptide-conjugated paclitaxel-docetaxel-based nanoparticles

doi: 10.1186/s40580-025-00487-0

Figure Lengend Snippet: In vivo biodistribution and retention level in the bloodstream of (Ac)FRRF-DTX NPs. ( a ) Scheme describing the in vivo distribution study of (Ac)FRRF-DTX NPs using BALB/c nude mice. ( b ) In vivo distribution over time of RITC-(Ac)FRRF-DTX NPs administered via tail vein injection in BALB/c nude mice. ( c ) Quantified graphs depicting fluorescent intensity in tumor regions ( n = 3). Images showing the measurement of fluorescence intensity from hourly extractions of organs and tumors in mice treated with RITC-(Ac)FRRF-DTX NPs ( d ) and treated with RITC-de-Boc-DTX ( e ). ( f ) Quantified graphs depicting fluorescent intensity in tumor tissues over time ( n = 3). ( g ) The concentration in the bloodstream of Sprague-Dawley rats treated with RITC-(Ac)FRRF-DTX NPs and RITC-de-Boc-DTX administered via tail vein injection ( n = 3). The AUC (h) and half-life (i) ( n = 3). *p < 0.05, **p < 0.01 and ***p < 0.001

Article Snippet: Also, the fluorescence intensity in nude mice was captured using a precision fluorescence analyzer (FOBI, CELLGENTEK, Republic of Korea).

Techniques: In Vivo, Injection, Fluorescence, Concentration Assay

Journal: Pharmaceutics

Article Title: Biodistribution of Intratracheal, Intranasal, and Intravenous Injections of Human Mesenchymal Stromal Cell-Derived Extracellular Vesicles in a Mouse Model for Drug Delivery Studies

doi: 10.3390/pharmaceutics15020548

Figure Lengend Snippet: In-vivo DiR-labeled MSC-EV biodistribution. DiR-EVs and DiR-PBS were administered by IV, IT and IN in BALB/c mice, and fluorescence was evaluated in vivo using an IVIS ® Imaging System LUMINA II. ( A ) Representative photographs of live animals are presented in supine and posterior position at different times following injection. ( B ) Quantification of fluorescence intensity through the region of interest (ROI) and measured as radiance (p/s/cm 2 /sr). Data are expressed as mean ± SD; ( n = 24/DiR-EVs and DiR-PBS).

Article Snippet: DiR-labeled MSC-EVs were injected in BALB/c mice of 6–8 weeks of age via intravenous (IV), intratracheal (IT) or intranasal (IN) administration and monitored over time using an IVIS ® Imaging System LUMINA II (PerkinElmer, Waltham, MA, USA).

Techniques: In Vivo, Labeling, Fluorescence, Imaging, Injection

Journal: Pharmaceutics

Article Title: Biodistribution of Intratracheal, Intranasal, and Intravenous Injections of Human Mesenchymal Stromal Cell-Derived Extracellular Vesicles in a Mouse Model for Drug Delivery Studies

doi: 10.3390/pharmaceutics15020548

Figure Lengend Snippet: Ex vivo analysis of DiR-labeled MSC-EV biodistribution. Representative image of ex-vivo-organ imaging, using IVIS ® ( A ). Quantification of the fluorescence as radiance (p/s/cm 2 /sr) is represented in ( B ) and expressed as average radiance ± SD ( n = 24/DiR-EVs and DiR-PBS). ( C ) Relative fluorescence in the different organs was assessed using fluorometric analysis after tissue homogenization, and it was calculated as AU/g of tissue. For all the data, subtraction of the DiR-PBS signal was performed (normalized fluorescent intensity, NFI). * p < 0.05; ** p < 0.01; *** p < 0.001 and **** p < 0.0001 after one-way ANOVA followed by Bonferroni’s multiple comparison. For **** p < 0.0001 against all the other groups.

Article Snippet: DiR-labeled MSC-EVs were injected in BALB/c mice of 6–8 weeks of age via intravenous (IV), intratracheal (IT) or intranasal (IN) administration and monitored over time using an IVIS ® Imaging System LUMINA II (PerkinElmer, Waltham, MA, USA).

Techniques: Ex Vivo, Labeling, Imaging, Fluorescence, Tissue Homogenization, Comparison